MedPage Today (4/7, George) reports, “New data explored the potential beneficial impact that glucagon-like peptide-1 (GLP-1) receptor agonists may have on neurodegenerative diseases.” Researchers at the annual American Academy of Neurology meeting “assessed how GLP-1 receptor agonists might influence cognitive and motor outcomes in Alzheimer’s disease, dementia, and Parkinson’s disease.” They said, “GLP-1 [receptor agonists] have already shown promise in reducing inflammation, oxidative stress, and neuronal damage, which are key factors in neurodegenerative diseases. GIP receptor agonism is demonstrating similar effects.” While GLP-1 receptor agonists have the potential to prevent and treat neurodegenerative diseases, researchers observed “we probably are not there yet.” (SOURCE: April 8, 2025 , APA Headlines)